Total Payments
$937,290
2024 Payments
$140,566
Companies
31
Transactions
963
Medicare Patients
3,574
Medicare Billing
$406,621
Payment Breakdown by Category
Other$691,093 (73.7%)
Travel$176,652 (18.8%)
Consulting$38,505 (4.1%)
Food & Beverage$25,690 (2.7%)
Research$5,250 (0.6%)
Education$99.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $688,068 | 189 | 73.4% |
| Travel and Lodging | $176,652 | 405 | 18.8% |
| Consulting Fee | $38,505 | 16 | 4.1% |
| Food and Beverage | $25,690 | 346 | 2.7% |
| Unspecified | $5,250 | 4 | 0.6% |
| Honoraria | $3,025 | 2 | 0.3% |
| Education | $99.95 | 1 | 0.0% |
Payments by Type
General
$932,040
959 transactions
Research
$5,250
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $383,090 | 384 | $0 (2024) |
| Astellas Pharma US Inc | $257,554 | 205 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $104,963 | 104 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $46,895 | 40 | $0 (2024) |
| Merck Sharp & Dohme LLC | $36,975 | 34 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $31,029 | 40 | $0 (2023) |
| Progenics Pharmaceuticals, Inc. | $30,153 | 28 | $0 (2023) |
| Janssen Biotech, Inc. | $17,184 | 23 | $0 (2024) |
| GENZYME CORPORATION | $8,221 | 7 | $0 (2023) |
| HISTOSONICS, INC. | $3,950 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140,566 | 139 | PFIZER INC. ($63,277) |
| 2023 | $215,687 | 198 | PFIZER INC. ($74,339) |
| 2022 | $125,784 | 123 | PFIZER INC. ($37,618) |
| 2021 | $51,778 | 36 | Astellas Pharma US Inc ($24,349) |
| 2020 | $89,201 | 78 | PFIZER INC. ($55,244) |
| 2019 | $144,498 | 157 | PFIZER INC. ($59,076) |
| 2018 | $132,118 | 180 | PFIZER INC. ($72,026) |
| 2017 | $37,657 | 52 | Astellas Pharma US Inc ($17,769) |
All Payment Transactions
963 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/16/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Food and Beverage | In-kind items and services | $38.61 | General |
| Category: OS | ||||||
| 12/13/2024 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Urology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $84.20 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Travel and Lodging | Cash or cash equivalent | $355.20 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Food and Beverage | Cash or cash equivalent | $88.73 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,248.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $57.23 | General |
| Category: Oncology | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Travel and Lodging | In-kind items and services | $1,007.93 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Travel and Lodging | In-kind items and services | $296.46 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $35.75 | General |
| Category: Urology | ||||||
| 10/27/2024 | HISTOSONICS,INC. | — | Food and Beverage | Cash or cash equivalent | $171.61 | General |
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $1,034.20 | General |
| Category: Oncology | ||||||
| 10/18/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,160.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $703.64 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $357.90 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $89.39 | General |
| Category: Oncology | ||||||
| 10/15/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,160.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $588.68 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $183.28 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,160.00 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $613.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,310 | 3 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 909 | 1,301 | $633,484 | $93,451 |
| 2022 | 14 | 888 | 1,339 | $666,341 | $98,850 |
| 2021 | 16 | 997 | 1,512 | $741,429 | $124,372 |
| 2020 | 12 | 780 | 1,093 | $559,827 | $89,948 |
Total Patients
3,574
Total Services
5,245
Medicare Billing
$406,621
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 284 | 463 | $199,090 | $35,074 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 138 | 220 | $125,992 | $22,904 | 18.2% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 24 | 35 | $38,360 | $7,413 | 19.3% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 31 | 31 | $35,495 | $5,995 | 16.9% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 37 | 39 | $24,705 | $4,731 | 19.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 62 | 85 | $64,600 | $4,631 | 7.2% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 40 | 40 | $33,040 | $3,941 | 11.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 21 | $13,293 | $2,187 | 16.5% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 11 | 16 | $30,120 | $1,495 | 5.0% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 46 | 48 | $7,056 | $1,331 | 18.9% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2023 | 16 | 17 | $9,620 | $1,108 | 11.5% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 23 | 25 | $4,375 | $814.50 | 18.6% |
| 51741 | Electronic assessment of bladder emptying | Facility | 2023 | 87 | 109 | $30,520 | $680.20 | 2.2% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 11 | 19 | $2,109 | $398.27 | 18.9% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 28 | 31 | $4,092 | $285.04 | 7.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 18 | $2,142 | $229.68 | 10.7% |
| 51741 | Electronic assessment of bladder emptying | Office | 2023 | 19 | 20 | $7,099 | $207.16 | 2.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 16 | 64 | $1,776 | $26.20 | 1.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 241 | 428 | $184,040 | $32,577 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 165 | $94,710 | $17,814 | 18.8% |
| 55875 | Insertion of needle or tube into prostate for radiation therapy | Facility | 2022 | 11 | 11 | $37,708 | $6,916 | 18.3% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 20 | 29 | $31,784 | $6,394 | 20.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 68 | 104 | $79,040 | $6,382 | 8.1% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2022 | 16 | 19 | $42,844 | $5,864 | 13.7% |
| 55700 | Biopsy of prostate gland | Office | 2022 | 27 | 27 | $30,915 | $5,088 | 16.5% |
About Dr. Edward Uchio, MD
Dr. Edward Uchio, MD is a Urology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1588648570.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Uchio, MD has received a total of $937,290 in payments from pharmaceutical and medical device companies, with $140,566 received in 2024. These payments were reported across 963 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($688,068).
As a Medicare-enrolled provider, Uchio has provided services to 3,574 Medicare beneficiaries, totaling 5,245 services with total Medicare billing of $406,621. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location Orange, CA
- Active Since 12/02/2005
- Last Updated 09/25/2014
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1588648570
Products in Payments
- XTANDI (Drug) $354,382
- Xtandi (Drug) $132,625
- Xofigo (Drug) $64,466
- TALZENNA (Drug) $56,774
- LYNPARZA (Drug) $46,895
- ORGOVYX (Drug) $39,136
- Nubeqa (Drug) $38,239
- Erleada (Drug) $35,418
- PYLARIFY (Drug) $30,153
- KEYTRUDA (Biological) $26,409
- SUTENT (Drug) $16,406
- ERLEADA (Drug) $10,232
- LYNPARZA (Biological) $8,566
- JEVTANA (Drug) $8,221
- Axumin (Drug) $3,288
- ADSTILADRIN (Biological) $1,874
- NANOKNIFE (Device) $1,856
- Non-Covered (Drug) $1,841
- PROVENGE (Drug) $1,400
- BRACANALYSIS CDX (Device) $525.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Orange
Jaime Landman, M.d, M.D
Urology — Payments: $831,352
Urology $831,352
Dr. Ralph Clayman, Md, MD
Urology — Payments: $675,958
Urology $675,958
Faysal Yafi, Md, MD
Urology — Payments: $360,816
Urology $360,816
Bela Denes, M.d, M.D
Urology — Payments: $235,399
Urology $235,399
Anne R Simoneau, Md, MD
Urology — Payments: $135,763
Urology $135,763
Dr. Jennifer Gruenenfelder, M.d, M.D
Urology — Payments: $104,260
Urology $104,260